Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 153Melanoma 133Lymphoma 124Prostatic Neoplasms 123Carcinoma, Non-Small-Cell Lung 113Multiple Myeloma 106Carcinoma, Renal Cell 92Ovarian Neoplasms 88Leukemia, Myeloid, Acute 83Sarcoma 82Lung Neoplasms 80Leukemia, Lymphocytic, Chronic, B-Cell 80Leukemia 79Colorectal Neoplasms 79Colonic Neoplasms 74Rectal Neoplasms 71Lymphoma, Non-Hodgkin 69Pancreatic Neoplasms 68Carcinoma, Ovarian Epithelial 66Neoplasms 65Lymphoma, Large B-Cell, Diffuse 65Brain Neoplasms 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Lymphoma, Follicular 58Kidney Neoplasms 58Glioblastoma 57Fallopian Tube Neoplasms 54Carcinoma, Hepatocellular 51Lymphoma, Mantle-Cell 50Central Nervous System Neoplasms 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × Camurati-Engelmann Syndrome × Clear all
NCT04501094 2022-03-22

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 13 charts

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡